A study of two ultra-long-acting HIV shots
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh more than 77 pounds (35 kg).
- You have had undetectable HIV (below 50 copies/mL) for at least the past year, including at your screening visit.
- You have been on your current daily HIV pills without a break for at least 6 months.
- Any previous change in your HIV meds was not because your virus stopped responding to treatment (viral load went above 200 copies/mL).
- You have never taken any long-acting HIV shots before, including cabotegravir or rilpivirine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
This study tests a new shot (called VH4011499) that may help control HIV. It is given together with another shot, cabotegravir, so you might not need to take daily pills. The study is for people who have never treated their HIV before.
This study tests whether a pharmacist can safely give long-acting HIV medications every 4 or 8 weeks. It aims to help more people with HIV get this treatment easily.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.